OS Therapies logo
OS Therapies
OSTX | AMEX
Chart Builder DCF Calculator
$0.68
-$0.06 (-8.72%)
At close: Nov 16, 2026, 4:00 PM ET
$0.68
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:55 PM ET

OS Therapies Company Profile

Company profile explained

Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.

Key Executives

Name Position
Paul A. Romness Founder, Chairman, President & Chief Executive Officer
Christopher Acevedo Chief Financial Officer
Francis Knuettel Chief Financial Officer
Gerald E. Commissiong Chief Business Officer
Jack Doll Chief of Staff
Kerry Clem Chief Commercial Officer
Robert G. Petit Chief Medical Officer & Chief Scientific Officer

Latest SEC Filings

Date Type Title
Oct 30, 2026 4 Filing
Oct 30, 2026 4 Filing
Oct 30, 2026 4 Filing
Oct 30, 2026 4 Filing
Oct 30, 2026 4 Filing
Oct 30, 2026 4 Filing
Oct 30, 2026 4 Filing
Oct 30, 2026 4 Filing
Oct 30, 2026 4 Filing
Oct 23, 2026 D Filing
View All SEC Filings ➞
OS Therapies
OS Therapies logo
Country United States
IPO Date Aug 1, 2024
Industry Biotechnology
Sector Healthcare
Employees 5
CEO Paul A. Romness

Contact Details

115 Pullman Crossing Road Grasonville, Maryland 21638 United States

Stock Details

Ticker Symbol OSTX
Exchange AMEX
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001795091
CUSIP Number 68764Y207
ISIN Number US68764Y2072
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.